Recently, some target therapies for prostate cancer have gained attention, including those targeting the prostate-specific membrane antigen (PSMA) [6], epidermal growth factor receptor (EGFR) [7], vascular endothelial growth factor (VEGF) [8], and BCL2-associated athanogene 1 L (BAG1L) [9]. The gene discussed is VEGFA; the disease is Familial prostate cancer.